Illumina, Inc. Hits New 52-Week High of $165.93, Up 54%

Illumina, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 165.93 on June 1, 2026. This achievement underscores the company's robust performance, particularly in the context of its impressive one-year performance of 54.04%, significantly outpacing the S&P 500's 28.56% during the same period. With a market capitalization of USD 22,890 million, Illumina operates as a mid-cap company, showcasing a strong financial position characterized by a price-to-earnings (P/E) ratio of 36.00. The company maintains a low debt-to-equity ratio of 0.16, indicating a solid balance sheet. Additionally, Illumina boasts a return on equity of 23.44%, reflecting effective management and operational efficiency. Despite not offering dividends, the stock's price-to-book ratio stands at 8.41, further illustrating its valuation in the market. The previous 52-week low for Illumina was recorded at USD 78.79, highlighting the significant upward trajectory the stock has experienced over the past year.